These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36858821)

  • 1. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.
    Rodríguez-Carrio J; Burska A; Conaghan PG; Dik WA; Biesen R; Eloranta ML; Cavalli G; Visser M; Boumpas DT; Bertsias G; Wahren-Herlenius M; Rehwinkel J; Frémond ML; Crow MK; Rönnblom L; Versnel MA; Vital EM
    Ann Rheum Dis; 2023 Jun; 82(6):754-762. PubMed ID: 36858821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
    Rodríguez-Carrio J; Burska A; Conaghan PG; Dik WA; Biesen R; Eloranta ML; Cavalli G; Visser M; Boumpas DT; Bertsias G; Wahren-Herlenius M; Rehwinkel J; Frémond ML; Crow MK; Ronnblom L; Vital E; Versnel M
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36882218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EULAR points to consider for the use of imaging to guide interventional procedures in patients with rheumatic and musculoskeletal diseases (RMDs).
    Dejaco C; Machado PM; Carubbi F; Bosch P; Terslev L; Tamborrini G; Sconfienza LM; Scirè CA; Ruetten S; van Rompay J; Proft F; Pitzalis C; Obradov M; Moe RH; Mascarenhas VV; Malattia C; Klauser AS; Kent A; Jans L; Hartung W; Hammer HB; Duftner C; Balint PV; Alunno A; Baraliakos X
    Ann Rheum Dis; 2022 Jun; 81(6):760-767. PubMed ID: 34893469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2021 EULAR points to consider to support people with rheumatic and musculoskeletal diseases to participate in healthy and sustainable paid work.
    Boonen A; Webers C; Butink M; Barten B; Betteridge N; Black DC; Bremander A; Boteva B; Brzezińska O; Chauhan L; Copsey S; Guimarães V; Gignac M; Glaysher J; Green F; Hoving JL; Marques ML; Smucrova H; Stamm TA; Wiek D; Wilkie R; Woolf AD; Burmester GR; Bijlsma JW; Verstappen SMM
    Ann Rheum Dis; 2023 Jan; 82(1):57-64. PubMed ID: 36109139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases.
    Najm A; Nikiphorou E; Kostine M; Richez C; Pauling JD; Finckh A; Ritschl V; Prior Y; Balážová P; Stones S; Szekanecz Z; Iagnocco A; Ramiro S; Sivera F; Dougados M; Carmona L; Burmester G; Wiek D; Gossec L; Berenbaum F
    RMD Open; 2019; 5(2):e001014. PubMed ID: 31565245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2019 EULAR points to consider for the assessment of competences in rheumatology specialty training.
    Sivera F; Alunno A; Najm A; Avcin T; Baraliakos X; Bijlsma JW; Badreh S; Burmester G; Cikes N; Da Silva JA; Damjanov N; Dougados M; Dudler J; Edwards CJ; Iagnocco A; Lioté F; Nikiphorou E; van Onna M; Stones SR; Vassilopoulos D; Haines C; Ramiro S
    Ann Rheum Dis; 2021 Jan; 80(1):65-70. PubMed ID: 32788400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology.
    Courvoisier DS; Lauper K; Kedra J; de Wit M; Fautrel B; Frisell T; Hyrich KL; Iannone F; Machado PM; Ørnbjerg LM; Rotar Z; Santos MJ; Stamm TA; Stones SR; Strangfeld A; Bergstra SA; Landewé RBM; Finckh A
    Ann Rheum Dis; 2022 Jun; 81(6):780-785. PubMed ID: 35058229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
    Krieckaert CL; van Tubergen A; Gehin JE; Hernández-Breijo B; Le Mélédo G; Balsa A; Böhm P; Cucnik S; Elkayam O; Goll GL; Hooijberg F; Jani M; Kiely PD; McCarthy N; Mulleman D; Navarro-Compán V; Payne K; Perry ME; Plasencia-Rodriguez C; Stones SR; Syversen SW; de Vries A; Ward KM; Wolbink G; Isaacs JD
    Ann Rheum Dis; 2023 Jan; 82(1):65-73. PubMed ID: 35551063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases.
    Gossec L; Kedra J; Servy H; Pandit A; Stones S; Berenbaum F; Finckh A; Baraliakos X; Stamm TA; Gomez-Cabrero D; Pristipino C; Choquet R; Burmester GR; Radstake TRDJ
    Ann Rheum Dis; 2020 Jan; 79(1):69-76. PubMed ID: 31229952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis.
    Boonen A; Putrik P; Marques ML; Alunno A; Abasolo L; Beaton D; Betteridge N; Bjørk M; Boers M; Boteva B; Fautrel B; Guillemin F; Mateus EF; Nikiphorou E; Péntek M; Pimentel Santos F; Severens JL; Verstappen SMM; Walker-Bone K; Wallman JK; Ter Wee MM; Westhovens R; Ramiro S
    Ann Rheum Dis; 2021 Sep; 80(9):1116-1123. PubMed ID: 33832966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.
    Dejaco C; Putrik P; Unger J; Aletaha D; Bianchi G; Bijlsma JW; Boonen A; Cikes N; Finckh A; Gossec L; Kvien TK; Madruga Dias J; Matteson EL; Sivera F; Stamm TA; Szekanecz Z; Wiek D; Zink A; Ramiro S; Buttgereit F
    RMD Open; 2018; 4(2):e000780. PubMed ID: 30714579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
    Burska A; Rodríguez-Carrio J; Biesen R; Dik WA; Eloranta ML; Cavalli G; Visser M; Boumpas DT; Bertsias G; Wahren-Herlenius M; Rehwinkel J; Frémond ML; Crow MK; Ronnblom L; Conaghan PG; Versnel M; Vital E
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36863752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis.
    Zabotti A; De Marco G; Gossec L; Baraliakos X; Aletaha D; Iagnocco A; Gisondi P; Balint PV; Bertheussen H; Boehncke WH; Damjanov NS; de Wit M; Errichetti E; Marzo-Ortega H; Protopopov M; Puig L; Queiro R; Ruscitti P; Savage L; Schett G; Siebert S; Stamm TA; Studenic P; Tinazzi I; Van den Bosch FE; van der Helm-van Mil A; Watad A; Smolen JS; McGonagle DG
    Ann Rheum Dis; 2023 Sep; 82(9):1162-1170. PubMed ID: 37295926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
    Drosos GC; Vedder D; Houben E; Boekel L; Atzeni F; Badreh S; Boumpas DT; Brodin N; Bruce IN; González-Gay MÁ; Jacobsen S; Kerekes G; Marchiori F; Mukhtyar C; Ramos-Casals M; Sattar N; Schreiber K; Sciascia S; Svenungsson E; Szekanecz Z; Tausche AK; Tyndall A; van Halm V; Voskuyl A; Macfarlane GJ; Ward MM; Nurmohamed MT; Tektonidou MG
    Ann Rheum Dis; 2022 Jun; 81(6):768-779. PubMed ID: 35110331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases.
    de Thurah A; Bosch P; Marques A; Meissner Y; Mukhtyar CB; Knitza J; Najm A; Østerås N; Pelle T; Knudsen LR; Šmucrová H; Berenbaum F; Jani M; Geenen R; Krusche M; Pchelnikova P; de Souza S; Badreh S; Wiek D; Piantoni S; Gwinnutt JM; Duftner C; Canhão HM; Quartuccio L; Stoilov N; Prior Y; Bijlsma JW; Zabotti A; Stamm TA; Dejaco C
    Ann Rheum Dis; 2022 Aug; 81(8):1065-1071. PubMed ID: 35470160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice.
    Ritschl V; Stamm TA; Aletaha D; Bijlsma JWJ; Böhm P; Dragoi RG; Dures E; Estévez-López F; Gossec L; Iagnocco A; Marques A; Moholt E; Nudel M; van den Bemt BJF; Viktil K; Voshaar M; de Thurah A; Carmona L
    Ann Rheum Dis; 2021 Jun; 80(6):707-713. PubMed ID: 33355152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs).
    Costantino F; Carmona L; Boers M; Backhaus M; Balint PV; Bruyn GA; Christensen R; Conaghan PG; Ferreira RJO; Garrido-Castro JL; Guillemin F; Hammer HB; van der Heijde D; Iagnocco A; Kortekaas MC; Landewé RB; Mandl P; Naredo E; Schmidt WA; Terslev L; Terwee CB; Thiele R; D'Agostino MA
    Ann Rheum Dis; 2021 Jul; 80(7):840-847. PubMed ID: 33483318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology.
    Najm A; Costantino F; Alivernini S; Alunno A; Bianchi E; Bignall J; Boyce B; Cañete JD; Carubbi F; Durez P; Fonseca JE; Just SA; Largo R; Manzo A; Maybury M; Naredo E; Orr C; Pitzalis C; Rivellese F; Romão VC; van Rompay J; Tas SW; Veale DJ; D'Agostino MA; Filer A
    Ann Rheum Dis; 2022 Dec; 81(12):1640-1646. PubMed ID: 35210263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.
    Gwinnutt JM; Wieczorek M; Balanescu A; Bischoff-Ferrari HA; Boonen A; Cavalli G; de Souza S; de Thurah A; Dorner TE; Moe RH; Putrik P; Rodríguez-Carrio J; Silva-Fernández L; Stamm T; Walker-Bone K; Welling J; Zlatković-Švenda MI; Guillemin F; Verstappen SMM
    Ann Rheum Dis; 2023 Jan; 82(1):48-56. PubMed ID: 35260387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
    Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
    Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.